Kyverna Therapeutics Inc (KYTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.160.00%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · KYTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-04 · Compared with 66 industry peers
KYTX — credit agreement
Dated 2026-07-09
Entry into a Material Definitive Agreement. As previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Loan and Security Agreement”) with Oxford Finance LLC, as collateral agent (the “Collateral Agent”), and certain lenders from time to time party thereto (the “Lenders”). The Loan and Security Agreement provides a non-dilutive term loan facility (the “Loan Facility”) of up to an aggregate principal amoun…
Why it matters: A clear plan would show how Kyverna aims to test miv-cel in progressive MS. A lack of a plan or a major delay would weaken that path.
Supportive ifKyverna shares more Stanford Phase 1 data in Q4 2026. It gives a naSPMS development plan by early 2027.
Worry ifKyverna delays the Stanford data past Q4 2026 or gives no naSPMS plan by early 2027.
Why it matters: An FDA filing decision is the next key test after submission. Acceptance would keep the path to a possible 2027 launch open.
Supportive ifThe FDA accepts the SPS BLA for review and sets a review timeline, with no request for more trial data.
Worry ifThe FDA refuses to file the SPS BLA or asks Kyverna for more trial data before review.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$267 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $876 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,413 loss on $10,000 · 54.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.